ValiRx plc AI Stock Analysis
Want to see GB:VAL full AI Analyst Report?
ValiRx plc (VAL) AI Stock Analysis
ValiRx plc
(LSE:VAL)
ValiRx's overall score of 49 is primarily dragged down by its deeply negative profitability margins, persistent cash burn, and a highly speculative valuation. However, the rating is slightly buoyed by a debt-free balance sheet and bullish short-to-medium-term technical indicators.
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 1.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.74M
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 1.12
- Revenue Growth
- -34.36%
- EPS Growth
- 57.45%
- Country
- UK
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat p...
ValiRx plc Financial Statement Overview
Summary
ValiRx exhibits negligible revenue, severe operating losses, and a persistent cash burn typical of clinical-stage biotechs. However, a virtually debt-free balance sheet provides a critical layer of financial stability.
Income Statement
15Very NegativeBalance Sheet
65PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.67K | 31.37K | 49.77K | 9,600 | 0 | 0 |
| Gross Profit | -112.46K | -6,250 | -217.22K | -246.04K | -224.27K | -228.79K |
| EBITDA | -1.49M | -2.18M | -1.86M | -2.04M | -2.38M | -1.45M |
| Net Income | -2.14M | -2.23M | -1.92M | -2.04M | -2.41M | -1.55M |
Balance Sheet | ||||||
| Total Assets | 2.77M | 2.63M | 4.26M | 3.13M | 3.98M | 3.52M |
| Cash, Cash Equivalents and Short-Term Investments | 970.56K | 791.61K | 1.56M | 174.68K | 1.14M | 593.67K |
| Total Debt | 0 | 1,395 | 11.86K | 22.07K | 37.71K | 58.72K |
| Total Liabilities | 120.82K | 235.10K | 346.41K | 226.51K | 149.65K | 109.56K |
| Stockholders Equity | 3.13M | 2.86M | 4.32M | 3.22M | 4.05M | 3.60M |
Cash Flow | ||||||
| Free Cash Flow | -1.36M | -1.52M | -1.62M | -2.08M | -1.71M | -1.26M |
| Operating Cash Flow | -1.36M | -1.51M | -1.58M | -1.77M | -1.71M | -1.26M |
| Investing Cash Flow | -2,587 | -13.58K | -38.16K | -306.18K | 0 | 0 |
| Financing Cash Flow | 1.81M | 759.35K | 3.00M | 1.12M | 2.26M | 7,343 |
ValiRx plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.14, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 46.21 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.
ValiRx plc Peers Comparison
Overall Rating
GB:VAL49Neutral
GB:SAR47Neutral
GB:HEMO46Neutral
GB:SCLP42Neutral
GB:TCF42Neutral
GB:IMM39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 1.85M | -0.74 | -71.49% | ― | -34.36% | 57.45% | |
| 47Neutral | GBP 23.75M | -6.04 | -188.01% | ― | ― | 28.78% | |
| 46Neutral | GBP 46.21M | -3.70 | -409.57% | ― | ― | 18.57% | |
| 42Neutral | GBP 95.77M | -4.51 | 128.87% | ― | -100.00% | -30.39% | |
| 42Neutral | GBP 4.51M | -1.65 | -93.92% | ― | ― | 55.56% | |
| 39Underperform | GBP 18.06M | -2.31 | -559.87% | ― | ― | 5.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:VAL | ValiRx plc | 0.14 | -0.11 | -45.10% | |
| GB:TCF | Evgen Pharma | 0.17 | -0.02 | -13.16% | |
| GB:IMM | ImmuPharma plc | 2.90 | -3.81 | -56.79% | |
| GB:SAR | Sareum Holdings | 14.50 | 1.50 | 11.54% | |
| GB:SCLP | Scancell Holdings | 79.00 | -15.50 | -16.40% | |
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 670.00 | -10.00 | -1.47% |
ValiRx plc Corporate Events
ValiRx sees value boost from Ambrose’s AM-Pharma acquisition
PositiveValiRx plc has highlighted the impact of Ambrose Healthcare Ltd’s acquisition of AM-Pharma on its own position, after Ambrose disclosed a deal worth up to €161 million that triggered a share price move in ValiRx. Through its 54.14% owned subsidiary V...
ValiRx tightens operations and bolsters cash as it refocuses pipeline and portfolio
PositiveValiRx has tightened its operations in the first half of 2026, fully implementing a lean strategy that cut administrative costs and delivered additional annual savings, while refocusing Inaphaea BioLabs on supporting the company’s own pipeline throug...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026